Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Syphilis | 3 | 2024 | 241 | 1.420 |
Why?
|
Anti-HIV Agents | 10 | 2023 | 4491 | 1.260 |
Why?
|
HIV Infections | 20 | 2024 | 17165 | 1.230 |
Why?
|
Sexual Partners | 3 | 2024 | 753 | 0.980 |
Why?
|
Homosexuality, Male | 5 | 2024 | 1273 | 0.920 |
Why?
|
Sexually Transmitted Diseases | 3 | 2024 | 628 | 0.860 |
Why?
|
Gonorrhea | 2 | 2024 | 343 | 0.820 |
Why?
|
Focus Groups | 1 | 2024 | 1378 | 0.620 |
Why?
|
Education, Continuing | 1 | 2018 | 114 | 0.610 |
Why?
|
Condoms | 1 | 2019 | 315 | 0.580 |
Why?
|
Parotid Gland | 1 | 2018 | 175 | 0.570 |
Why?
|
Burkitt Lymphoma | 1 | 2018 | 333 | 0.510 |
Why?
|
Qualitative Research | 1 | 2024 | 2963 | 0.440 |
Why?
|
Peritonitis, Tuberculous | 1 | 2013 | 6 | 0.440 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1091 | 0.400 |
Why?
|
Counseling | 1 | 2019 | 1548 | 0.380 |
Why?
|
Public Health | 2 | 2024 | 2653 | 0.350 |
Why?
|
Education, Medical | 2 | 2018 | 1727 | 0.340 |
Why?
|
Spouse Abuse | 1 | 2011 | 179 | 0.340 |
Why?
|
Drug Prescriptions | 1 | 2019 | 1673 | 0.330 |
Why?
|
Homosexuality, Female | 1 | 2011 | 159 | 0.330 |
Why?
|
Bisexuality | 1 | 2011 | 274 | 0.320 |
Why?
|
Opportunistic Infections | 2 | 2023 | 377 | 0.300 |
Why?
|
Transsexualism | 1 | 2011 | 177 | 0.290 |
Why?
|
Gender Identity | 2 | 2023 | 698 | 0.280 |
Why?
|
Drug Resistance, Viral | 3 | 2021 | 859 | 0.270 |
Why?
|
HIV-1 | 3 | 2018 | 6849 | 0.260 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 3242 | 0.260 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5325 | 0.240 |
Why?
|
Bedding and Linens | 1 | 2023 | 41 | 0.210 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2013 | 2125 | 0.180 |
Why?
|
Relapsing Fever | 1 | 2020 | 24 | 0.180 |
Why?
|
Borrelia | 1 | 2020 | 66 | 0.180 |
Why?
|
Chlamydia Infections | 1 | 2024 | 362 | 0.180 |
Why?
|
Meningoencephalitis | 1 | 2020 | 83 | 0.180 |
Why?
|
Cryptococcosis | 1 | 2020 | 104 | 0.170 |
Why?
|
Exanthema | 1 | 2024 | 504 | 0.170 |
Why?
|
Reproductive Health Services | 1 | 2020 | 87 | 0.160 |
Why?
|
Arthritis | 1 | 2024 | 666 | 0.160 |
Why?
|
Humans | 37 | 2024 | 760621 | 0.150 |
Why?
|
Mycobacterium Infections | 1 | 2019 | 121 | 0.150 |
Why?
|
Lung Diseases, Fungal | 1 | 2019 | 126 | 0.150 |
Why?
|
Ambulatory Care Facilities | 2 | 2023 | 926 | 0.150 |
Why?
|
Dendritic Cells | 2 | 2020 | 2725 | 0.150 |
Why?
|
Bronchiectasis | 1 | 2019 | 139 | 0.140 |
Why?
|
Mycobacterium | 1 | 2019 | 250 | 0.140 |
Why?
|
South Africa | 4 | 2023 | 1821 | 0.140 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2018 | 410 | 0.140 |
Why?
|
Interviews as Topic | 1 | 2024 | 2659 | 0.140 |
Why?
|
Sex Education | 1 | 2017 | 92 | 0.140 |
Why?
|
Education, Nursing | 1 | 2017 | 79 | 0.140 |
Why?
|
New York City | 1 | 2019 | 724 | 0.140 |
Why?
|
Inservice Training | 1 | 2018 | 375 | 0.130 |
Why?
|
New England | 1 | 2019 | 1050 | 0.130 |
Why?
|
Sarcoma, Kaposi | 1 | 2019 | 376 | 0.130 |
Why?
|
Models, Economic | 1 | 2020 | 719 | 0.130 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2021 | 1894 | 0.130 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2019 | 662 | 0.120 |
Why?
|
HIV Protease Inhibitors | 1 | 2017 | 432 | 0.120 |
Why?
|
Male | 20 | 2024 | 359744 | 0.120 |
Why?
|
Microbial Sensitivity Tests | 2 | 2019 | 1949 | 0.120 |
Why?
|
Anti-Retroviral Agents | 2 | 2023 | 1779 | 0.110 |
Why?
|
United States | 7 | 2023 | 72461 | 0.110 |
Why?
|
Virus Replication | 2 | 2020 | 2432 | 0.110 |
Why?
|
Sexual Behavior | 1 | 2023 | 2086 | 0.110 |
Why?
|
Boston | 2 | 2024 | 9280 | 0.110 |
Why?
|
Headache | 1 | 2020 | 1249 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3085 | 0.100 |
Why?
|
Diagnosis, Differential | 4 | 2024 | 12965 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3205 | 0.100 |
Why?
|
Omentum | 1 | 2013 | 169 | 0.100 |
Why?
|
Face | 1 | 2018 | 1017 | 0.100 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1764 | 0.100 |
Why?
|
Phylogeny | 1 | 2019 | 2775 | 0.100 |
Why?
|
Viral Load | 4 | 2021 | 3322 | 0.090 |
Why?
|
Haiti | 1 | 2013 | 549 | 0.090 |
Why?
|
Curriculum | 2 | 2022 | 3718 | 0.090 |
Why?
|
Housing | 1 | 2015 | 665 | 0.090 |
Why?
|
Cystic Fibrosis | 1 | 2019 | 1274 | 0.080 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 5508 | 0.080 |
Why?
|
Live Birth | 1 | 2013 | 512 | 0.080 |
Why?
|
Patient Acceptance of Health Care | 1 | 2023 | 3164 | 0.080 |
Why?
|
Mass Screening | 1 | 2023 | 5423 | 0.070 |
Why?
|
Primary Health Care | 1 | 2023 | 4647 | 0.070 |
Why?
|
Uganda | 2 | 2021 | 1324 | 0.070 |
Why?
|
Medical Oncology | 1 | 2018 | 2313 | 0.070 |
Why?
|
Female | 15 | 2023 | 391270 | 0.070 |
Why?
|
Biopsy | 1 | 2018 | 6771 | 0.070 |
Why?
|
Crohn Disease | 1 | 2018 | 2275 | 0.060 |
Why?
|
Antitubercular Agents | 1 | 2013 | 1373 | 0.060 |
Why?
|
HIV | 2 | 2023 | 1579 | 0.060 |
Why?
|
Massachusetts | 3 | 2023 | 8803 | 0.060 |
Why?
|
Monkeypox virus | 1 | 2023 | 42 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2020 | 5397 | 0.050 |
Why?
|
Contact Tracing | 1 | 2024 | 268 | 0.050 |
Why?
|
Atherosclerosis | 1 | 2017 | 3517 | 0.050 |
Why?
|
Alkynes | 1 | 2021 | 313 | 0.050 |
Why?
|
Premature Birth | 1 | 2013 | 1771 | 0.050 |
Why?
|
Cyclopropanes | 1 | 2021 | 431 | 0.040 |
Why?
|
Benzoxazines | 1 | 2021 | 309 | 0.040 |
Why?
|
Young Adult | 2 | 2024 | 58741 | 0.040 |
Why?
|
Culicidae | 1 | 2020 | 108 | 0.040 |
Why?
|
Ultrasonography | 1 | 2013 | 5961 | 0.040 |
Why?
|
Speech Disorders | 1 | 2020 | 180 | 0.040 |
Why?
|
Adult | 6 | 2024 | 219994 | 0.040 |
Why?
|
Louisiana | 1 | 2019 | 104 | 0.040 |
Why?
|
Chaperonin 60 | 1 | 2019 | 97 | 0.040 |
Why?
|
Confusion | 1 | 2020 | 279 | 0.040 |
Why?
|
Middle Aged | 7 | 2024 | 220352 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2023 | 80372 | 0.040 |
Why?
|
DNA, Ribosomal | 1 | 2019 | 285 | 0.040 |
Why?
|
Texas | 1 | 2019 | 401 | 0.040 |
Why?
|
Cerebrospinal Fluid | 1 | 2020 | 544 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2020 | 4353 | 0.040 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 117 | 0.040 |
Why?
|
Pandemics | 3 | 2023 | 8624 | 0.040 |
Why?
|
DNA-Directed RNA Polymerases | 1 | 2019 | 367 | 0.030 |
Why?
|
Syndrome | 1 | 2023 | 3280 | 0.030 |
Why?
|
Quality of Life | 3 | 2023 | 13308 | 0.030 |
Why?
|
Bilirubin | 1 | 2017 | 438 | 0.030 |
Why?
|
Cerebral Infarction | 1 | 2020 | 982 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2021 | 2569 | 0.030 |
Why?
|
Treatment Failure | 1 | 2021 | 2648 | 0.030 |
Why?
|
Pregnancy | 2 | 2017 | 29749 | 0.030 |
Why?
|
Myeloid Cells | 1 | 2020 | 820 | 0.030 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2019 | 1006 | 0.030 |
Why?
|
Comorbidity | 2 | 2020 | 10551 | 0.030 |
Why?
|
Africa South of the Sahara | 1 | 2017 | 742 | 0.030 |
Why?
|
DNA, Bacterial | 1 | 2019 | 1456 | 0.030 |
Why?
|
Drug Interactions | 1 | 2018 | 1428 | 0.030 |
Why?
|
Cultural Competency | 1 | 2017 | 294 | 0.030 |
Why?
|
Drug Resistance | 1 | 2020 | 1617 | 0.030 |
Why?
|
Fatigue | 1 | 2020 | 1544 | 0.030 |
Why?
|
Cells, Cultured | 2 | 2020 | 18957 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2020 | 1827 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2018 | 857 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2013 | 26181 | 0.030 |
Why?
|
Ambulatory Care | 1 | 2023 | 2781 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2019 | 2698 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2203 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2018 | 10344 | 0.020 |
Why?
|
Monocytes | 1 | 2020 | 2575 | 0.020 |
Why?
|
Cost of Illness | 1 | 2020 | 1940 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2017 | 65017 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2017 | 1613 | 0.020 |
Why?
|
Neoplasms | 1 | 2018 | 22072 | 0.020 |
Why?
|
Risk Factors | 3 | 2023 | 74359 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2023 | 3986 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2020 | 3047 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2019 | 4713 | 0.020 |
Why?
|
Surgical Procedures, Operative | 1 | 2018 | 1913 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2020 | 4742 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4550 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2017 | 3106 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 3696 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2020 | 7593 | 0.020 |
Why?
|
Societies, Medical | 1 | 2018 | 3905 | 0.020 |
Why?
|
Bacterial Proteins | 1 | 2019 | 3826 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2017 | 4433 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2017 | 4490 | 0.020 |
Why?
|
Health Promotion | 1 | 2017 | 2206 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9411 | 0.010 |
Why?
|
Cell Line | 1 | 2017 | 15620 | 0.010 |
Why?
|
Palliative Care | 1 | 2018 | 3607 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2018 | 3388 | 0.010 |
Why?
|
Health Status | 1 | 2015 | 4081 | 0.010 |
Why?
|
Aged | 3 | 2020 | 169152 | 0.010 |
Why?
|
Research Design | 1 | 2017 | 6180 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2019 | 7408 | 0.010 |
Why?
|
Time Factors | 1 | 2020 | 40165 | 0.010 |
Why?
|
Cohort Studies | 1 | 2020 | 41335 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 20509 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2017 | 25942 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2018 | 15697 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2015 | 7818 | 0.010 |
Why?
|
Depression | 1 | 2015 | 8044 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2018 | 13630 | 0.010 |
Why?
|
Hospitalization | 1 | 2015 | 10790 | 0.010 |
Why?
|
Brain | 1 | 2020 | 26951 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36290 | 0.010 |
Why?
|
Child | 1 | 2019 | 79806 | 0.010 |
Why?
|
Animals | 1 | 2020 | 167963 | 0.000 |
Why?
|
Concepts
(182)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(62)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_